To assess the efficacy of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced HIV-1 patients by describing the proportion of patients who experienced virological failure (VF) at W24. Secondary objectives were to follow HIV-1 plasma viral load (pVL) after W24, the proportion of patients who underwent dual/monotherapy and death.Patients from the ANRS CO3 Aquitaine Cohort who were prescribed TRIO regimen between February 2007 and September 2018 were classified into 2 groups based on their pVL at inclusion: the virological failure group (VFG) with pVL50 copies/mL and the virologically suppressed group (VSG) with pVL50 copies/mL. Impact of baseline pVL and Genotypic susceptibility score (GSS) on VF was analyzed.184 patients were enrolled including 123 (66.8%) and 61 (33.2%) from the VFG and VSG groups, respectively. The median time of follow-up was 7.5 (IQR 4.1-9.6) years and 29 (15.8%) patients died. Thirty-seven (25.5%) patients experienced VF at W24, including 32/145 (32.7%) in VFG and 5/47 (10.6%) in VSG (p0.01). Resistance-associated mutations were detected in integrase, reverse transcriptase and protease for 7/37 (18.9%), 3/37 (8.1%) and 1/37 (2.7%) patients respectively. High pVL and GSS at baseline were independently associated with VF. At the last visit, 76/184 (41.3%) patients still received TRIO, while 55/184 (29.9%) received dual therapy and 1/184 (0.5%) PI-monotherapy. Among the 56 patients with dual/monotherapy, 51 (96.2%) had pVL50 copies/mL.Despite a high level of mutation resistance at baseline, long-term virological follow-up was favorable and one third of patients were eligible for drug-reducing strategies.